Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Emphysema
Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema
This study will evaluate the effects of baseline collateral ventilation status on outcomes following treatment with AeriSeal System in patients with advanced upper-lobe predominant heterogenous emphysema.
- Trial name
- CV+/- (NCT01520740)
- Testing
- Emphysematous Lung Sealant
- Where
- 13 sites in Germany, Israel
- Volunteers
- 100 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease
Dose Finding Study of CHF 4226 for Treating Patients With COPD
The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
- Trial name
- NCT00605891
- Testing
- carmoterol (CHF 4226), salmeterol
- Where
- 50 sites in United States, Czechia and 4 more
- Volunteers
- 278 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
- Trial name
- NCT04926233
- Testing
- Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat®
- Where
- United States
- Volunteers
- 1,371,146 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366
CHF6366 is a novel bifunctional compound displaying both muscarinic receptor antagonist and β2-adrenergic receptor agonist properties (MABA), with the potential to deliver optimal bronchodilation after inhalation dosing via two…
- Trial name
- NCT03378648
- Testing
- CHF6366, umeclidinium bromide and vilanterol trifenatate
- Where
- United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
The study will evaluate bioequivalence, pharmacokinetics, safety, and tolerability of Budesonide, Glycopyrronium and Formoterol (BGF) metered dose inhaler (MDI) formulated with hydrofluoroolefin (HFO) [Test] and hydrofluoroalkane…
- Trial name
- NCT05569421
- Testing
- Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study was to determine the pharmacokinetic comparability of 84 µg ipratropium bromide HFA-134a inhalation aerosol and 84 µg ATROVENT® CFC Inhalation Aerosol in COPD patients
- Trial name
- NCT02236169
- Testing
- Ipratropium bromide HFA-134a inhalation aerosol, Atrovent CFC inhalation aerosol
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece
The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently…
- Trial name
- NCT04672941
- Testing
- Tiotropium bromide plus Olodaterol
- Where
- 2 sites in Greece
- Volunteers
- 1,396 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.
- Trial name
- NCT00868231
- Testing
- Aclidinium bromide 400 μg bid, Tiotropium 18 μg once-daily
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients
- Trial name
- NCT00380133
- Testing
- SB681323, Prednisolone
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105948
- Testing
- Mepolizumab
- Where
- 116 sites in United States, Australia and 14 more
- Volunteers
- 837 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00752414
- Testing
- MP-376 (Levofloxacin solution for Inhalation)
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Amgen
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD
This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days), three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and safety of two dose levels of a dual pharmacology…
- Trial name
- NCT02109406
- Testing
- AZD2115 Dose 1, AZD 2115, Dose 2
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-related quality of life (HRQoL).
- Trial name
- RECORD (NCT05311306)
- Where
- 62 sites in Germany
- Volunteers
- 475 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT05987371
- Testing
- TQC3721 suspension for inhalation, Salbutamol sulfate inhalation aerosol
- Where
- 11 sites in China
- Volunteers
- 75 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease, COPD
Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults
This study aims to assess the effect of EP395 against an induced inflammation of the lung. In addition, further data about the safety and tolerability of EP395 will be collected.
- Trial name
- NCT05516316
- Testing
- EP395
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- EpiEndo Pharmaceuticals
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT03118765
- Testing
- GSP304 (tiotropium bromide) Inhalation Solution, Spiriva® Respimat® inhalation spray
- Where
- 25 sites in United States
- Volunteers
- 155 people
- Sponsor
- Glenmark Specialty S.A.
Heart Failure, Chronic Obstructive Pulmonary Disease
Coventry Outcomes Study of Seniors (COSS): A Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention on the Incidence of Nonelective Hospitalizations in a Medicare Population
The investigators are studying the impact of the interventions of a multidisciplinary team (MDT) - consisting of a Coventry case manager, social worker, and medical director, alongside a Medco specialist pharmacist - on the…
- Conditions
- Heart Failure, Chronic Obstructive Pulmonary Disease, Cardiovascular Disease, Diabetes
- Trial name
- COSS (NCT01014884)
- Testing
- Multidisciplinary team interventions, Multidisciplinary team bimonthly visits either in person or via telephone., Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager
- Where
- 2 sites in United States
- Volunteers
- 2,150 people
- Sponsor
- Medco Health Solutions, Inc.
Chronic Obstructive Pulmonary Disease
Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD).
- Trial name
- NCT01333904
- Testing
- PUR118
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Pulmatrix Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.